Literature DB >> 33362228

Hemodynamic and metabolic recovery in acute myocardial infarction-related cardiogenic shock is more rapid among patients presenting with out-of-hospital cardiac arrest.

Jakob Josiassen1, Ole Kristian Lerche Helgestad2,3, Jacob Eifer Møller1,2,3, Jesper Kjaergaard1, Henrik Frederiksen Hoejgaard4, Henrik Schmidt4, Lisette Okkels Jensen2, Lene Holmvang1,5, Hanne Berg Ravn6,5, Christian Hassager1,5.   

Abstract

BACKGROUND: Most studies in acute myocardial infarction complicated by cardiogenic shock (AMICS) include patients presenting with and without out-of-hospital cardiac arrest (OHCA). The aim was to compare OHCA and non-OHCA AMICS patients in terms of hemodynamics, management in the intensive care unit (ICU) and outcome.
METHODS: From a cohort corresponding to two thirds of the Danish population, all patients with AMICS admitted from 2010-2017 were individually identified through patient records.
RESULTS: A total of 1716 AMICS patients were identified of which 723 (42%) presented with OHCA. A total of 1532 patients survived to ICU admission. At the time of ICU arrival, there were no differences between OHCA and non-OHCA AMICS patients in variables commonly used in the AMICS definition (mean arterial pressure (MAP) (72mmHg vs 70mmHg, p = 0.12), lactate (4.3mmol/L vs 4.0mmol/L, p = 0.09) and cardiac output (CO) (4.6L/min vs 4.4L/min, p = 0.30)) were observed. However, during the initial days of ICU treatment OHCA patients had a higher MAP despite a lower need for vasoactive drugs, higher CO, SVO2 and lactate clearance compared to non-OHCA patients (p<0.05 for all). In multivariable analysis outcome was similar but cause of death differed significantly with hypoxic brain injury being leading cause in OHCA and cardiac failure in non-OHCA AMICS patients.
CONCLUSION: OHCA and non-OHCA AMICS patients initially have comparable metabolic and hemodynamic profiles, but marked differences develop between the groups during the first days of ICU treatment. Thus, pooling of OHCA and non-OHCA patients as one clinical entity in studies should be done with caution.

Entities:  

Year:  2020        PMID: 33362228      PMCID: PMC7757873          DOI: 10.1371/journal.pone.0244294

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  34 in total

1.  Mixed venous oxygen saturation in AMI.

Authors:  G R Nimmo
Journal:  Am Heart J       Date:  1992-06       Impact factor: 4.749

2.  Targeted temperature management at 33°C versus 36°C after cardiac arrest.

Authors:  Niklas Nielsen; Jørn Wetterslev; Tobias Cronberg; David Erlinge; Yvan Gasche; Christian Hassager; Janneke Horn; Jan Hovdenes; Jesper Kjaergaard; Michael Kuiper; Tommaso Pellis; Pascal Stammet; Michael Wanscher; Matt P Wise; Anders Åneman; Nawaf Al-Subaie; Søren Boesgaard; John Bro-Jeppesen; Iole Brunetti; Jan Frederik Bugge; Christopher D Hingston; Nicole P Juffermans; Matty Koopmans; Lars Køber; Jørund Langørgen; Gisela Lilja; Jacob Eifer Møller; Malin Rundgren; Christian Rylander; Ondrej Smid; Christophe Werer; Per Winkel; Hans Friberg
Journal:  N Engl J Med       Date:  2013-11-17       Impact factor: 91.245

3.  Understanding How Cardiac Arrest Complicates the Analysis of Clinical Trials of Cardiogenic Shock.

Authors:  Jacob C Jentzer; Sean van Diepen; Timothy D Henry
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-08-31

4.  Haemodynamic and oxygen transport effects of propofol infusion in critically ill adults.

Authors:  G R Nimmo; S J Mackenzie; I S Grant
Journal:  Anaesthesia       Date:  1994-06       Impact factor: 6.955

5.  Prognostic implication of out-of-hospital cardiac arrest in patients with cardiogenic shock and acute myocardial infarction.

Authors:  Sarah Ostenfeld; Matias Greve Lindholm; Jesper Kjaergaard; John Bro-Jeppesen; Jacob Eifer Møller; Michael Wanscher; Christian Hassager
Journal:  Resuscitation       Date:  2014-12-02       Impact factor: 5.262

6.  Risk factors of late cardiogenic shock and mortality in ST-segment elevation myocardial infarction patients.

Authors:  Laust Obling; Martin Frydland; Rikke Hansen; Ole Kristian Møller-Helgestad; Matias Greve Lindholm; Lene Holmvang; Hanne Berg Ravn; Sebastian Wiberg; Jakob Hartvig Thomsen; Lisette Okkels Jensen; Jesper Kjærgaard; Jacob Eifer Møller; Christian Hassager
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2017-04-28

7.  Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective.

Authors:  Robert J Goldberg; Frederick A Spencer; Joel M Gore; Darleen Lessard; Jorge Yarzebski
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

8.  Intraaortic balloon support for myocardial infarction with cardiogenic shock.

Authors:  Holger Thiele; Uwe Zeymer; Franz-Josef Neumann; Miroslaw Ferenc; Hans-Georg Olbrich; Jörg Hausleiter; Gert Richardt; Marcus Hennersdorf; Klaus Empen; Georg Fuernau; Steffen Desch; Ingo Eitel; Rainer Hambrecht; Jörg Fuhrmann; Michael Böhm; Henning Ebelt; Steffen Schneider; Gerhard Schuler; Karl Werdan
Journal:  N Engl J Med       Date:  2012-08-26       Impact factor: 91.245

9.  Intensive care unit mortality after cardiac arrest: the relative contribution of shock and brain injury in a large cohort.

Authors:  Virginie Lemiale; Florence Dumas; Nicolas Mongardon; Olivier Giovanetti; Julien Charpentier; Jean-Daniel Chiche; Pierre Carli; Jean-Paul Mira; Jerry Nolan; Alain Cariou
Journal:  Intensive Care Med       Date:  2013-08-14       Impact factor: 17.440

10.  Development and performance of a novel vasopressor-driven mortality prediction model in septic shock.

Authors:  Saraschandra Vallabhajosyula; Jacob C Jentzer; Aditya A Kotecha; Dennis H Murphree; Erin F Barreto; Ashish K Khanna; Vivek N Iyer
Journal:  Ann Intensive Care       Date:  2018-11-22       Impact factor: 6.925

View more
  1 in total

Review 1.  Impella to Treat Acute Myocardial Infarct-Related Cardiogenic Shock.

Authors:  Jacob Eifer Møller; Jesper Kjaergaard; Christian Juhl Terkelsen; Christian Hassager
Journal:  J Clin Med       Date:  2022-04-26       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.